Tel Aviv, Tel Aviv District, Israel In 1995 was created Medica Venture Partners, which is appeared as VC. The company was established in Asia in Israel. The main department of described VC is located in the Herzliya.
The fund has exact preference in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Dynogen Pharmaceuticals, FlowMedica, InterCure. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Life Science, Medical.
The fund was created by Ehud Geller. We also calculated 4 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Medica Venture Partners, startups are often financed by Oxford Bioscience Partners, True North Venture Partners, True North Partners. The meaningful sponsors for the fund in investment in the same round are Oxford Bioscience Partners, SCP Vitalife Partners, Pitango Venture Capital. In the next rounds fund is usually obtained by Oxford Bioscience Partners, SCP Vitalife Partners, OrbiMed.
The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2012. Comparing to the other companies, this Medica Venture Partners performs on 14 percentage points more the average number of lead investments. The top activity for fund was in 2003. Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Alwin Capital | Beijing, Beijing, China |
| Berlin Metropolitan Ventures | Berlin, Berlin, Germany |
| Caymus Equity | New York, New York, United States |
| CKA Capital Ltd | England, London, United Kingdom |
| Convergent Ventures | California, Los Angeles, United States |
| Dongyuan Huixin Equity Investment Fund Management | China, Shanghai |
| EPOS | Capital Region of Denmark, Denmark, Hovedstaden |
| FUNKE Digital | Berlin, Berlin, Germany |
| GateHub | England, London, United Kingdom |
| Irelandia Aviation | County Dublin, Dublin, Ireland |
| Kubota Vietnam Ltd | Chí Linh, Hải Dương Province, Vietnam |
| Kyoritsu Corporation | Japan, Setagaya |
| Playford Capital | Adelaide, Australia, South Australia |
| Primal Capital | Chiyoda, Japan |
| Quan Technology Fund | Geneva, Geneve, Switzerland |
| Rovi Corporation | California, Santa Clara, United States |
| Various Investors | - |
| Wanxiang Healthcare Investments | Elgin, Illinois, United States |
| Zhidian Touzi | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Regentis Biomaterials | $10M | 14 May 2012 | Israel, North District, Israel | ||
Regentis Biomaterials | $7M | 21 Aug 2007 | Israel, North District, Israel | ||
InterCure | $3M | 13 Apr 2005 | Ra'anana, HaMerkaz, Israel | ||
Remon Medical Technologies | $10M | 10 Jan 2005 | Israel, North District | ||
FlowMedica | $5M | 11 Oct 2004 | Fremont, California, United States | ||
Dynogen Pharmaceuticals | $50M | 20 Apr 2004 | Boston, Massachusetts, United States | ||
Percutaneous Valve Technologies (PVT) | $14M | 01 Jan 2003 | New Jersey, United States | ||
InterCure | $4M | 30 Oct 2001 | Ra'anana, HaMerkaz, Israel | ||
Percutaneous Valve Technologies (PVT) | $5M | 01 Jan 2001 | New Jersey, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Regentis Biomaterials | $10M | 14 May 2012 | Israel, North District, Israel | ||
Regentis Biomaterials | $7M | 21 Aug 2007 | Israel, North District, Israel | ||
InterCure | $3M | 13 Apr 2005 | Ra'anana, HaMerkaz, Israel | ||
Remon Medical Technologies | $10M | 10 Jan 2005 | Israel, North District | ||
FlowMedica | $5M | 11 Oct 2004 | Fremont, California, United States | ||
Dynogen Pharmaceuticals | $50M | 20 Apr 2004 | Boston, Massachusetts, United States | ||
Percutaneous Valve Technologies (PVT) | $14M | 01 Jan 2003 | New Jersey, United States | ||
InterCure | $4M | 30 Oct 2001 | Ra'anana, HaMerkaz, Israel | ||
Percutaneous Valve Technologies (PVT) | $5M | 01 Jan 2001 | New Jersey, United States |
